<?xml version="1.0" encoding="UTF-8"?>
<ref id="b1-1031835">
 <label>1.</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Kantarjian</surname>
    <given-names>HM</given-names>
   </name>
   <name>
    <surname>Hochhaus</surname>
    <given-names>A</given-names>
   </name>
   <name>
    <surname>Saglio</surname>
    <given-names>G</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial</article-title>. 
  <source>Lancet Oncol</source>. 
  <year>2011</year>;
  <volume>12</volume>(
  <issue>9</issue>):
  <fpage>841</fpage>â€“
  <lpage>851</lpage>.
  <pub-id pub-id-type="pmid">21856226</pub-id>
 </mixed-citation>
</ref>
